Cellino Closes $16 Million Seed Financing Led by The Engine and Khosla Ventures
Summary
Top-tier investor syndicate co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, announced the closing of a $16M Seed financing round. The proprietary platform converges breakthrough technologies across optics, biology, and machine learning to engineer high functionality cells with unrivaled consistency and yield. “This seed financing round enables us to build towards a democratized future for autologous cells and tissues,” said Nabiha Saklayen, Ph.D., CEO & Co-Founder, Cellino. “I’m thrilled to be leading a team that brings together diverse backgrounds spanning laser physics, stem cell biology, and machine learning, to achieve our shared mission to increase patient access to custom regenerative therapies.” “Companies that disrupt entire industries and processes don’t normally originate from a single discipline,” said Alex Morgan, M.D., Ph.D., Partner at Khosla Ventures. The company’s leadership team has the experience and vision to make it a reality.” Cellino’s platform automates stem cell production using image-guided machine learning, single-cell laser processing, and robotics.